Corient Private Wealth LP Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Corient Private Wealth LP purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 24,244 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,007,000.

Other large investors also recently made changes to their positions in the company. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. increased its stake in ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter worth about $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ANIP shares. Canaccord Genuity Group decreased their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim decreased their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

ANI Pharmaceuticals Trading Up 1.6%

ANIP stock opened at $73.06 on Thursday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 15.75 and a beta of 0.45. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The business has a fifty day simple moving average of $79.12 and a 200-day simple moving average of $78.53. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter last year, the firm earned $1.80 earnings per share. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insider Buying and Selling

In other news, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director directly owned 38,878 shares in the company, valued at $3,144,452.64. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares in the company, valued at $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 27,237 shares of company stock worth $2,155,105. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.